MXPA05008961A - Tratamiento de osteolisis excesiva con compuestos de indolinona. - Google Patents

Tratamiento de osteolisis excesiva con compuestos de indolinona.

Info

Publication number
MXPA05008961A
MXPA05008961A MXPA05008961A MXPA05008961A MXPA05008961A MX PA05008961 A MXPA05008961 A MX PA05008961A MX PA05008961 A MXPA05008961 A MX PA05008961A MX PA05008961 A MXPA05008961 A MX PA05008961A MX PA05008961 A MXPA05008961 A MX PA05008961A
Authority
MX
Mexico
Prior art keywords
excessive
osteolyisis
treatment
indolinone compounds
compounds
Prior art date
Application number
MXPA05008961A
Other languages
English (en)
Inventor
Anne-Marie O'farrell
Original Assignee
Sugen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen Inc filed Critical Sugen Inc
Publication of MXPA05008961A publication Critical patent/MXPA05008961A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Los compuestos de formula I y formula II, (ver formulas (I) y (II)) como se describen en la presente invencion, son utiles para tratar osteolisis excesiva, mediante la inhibicion del desarrollo del osteoclasto mediada por M-CSF; los compuestos tambien son utiles para la inhibicion de la fosforilacion del CSF1R, y para el tratamiento de canceres que expresan CSF1R.
MXPA05008961A 2003-02-24 2004-02-23 Tratamiento de osteolisis excesiva con compuestos de indolinona. MXPA05008961A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44886103P 2003-02-24 2003-02-24
US10/780,917 US20040209937A1 (en) 2003-02-24 2004-02-19 Treatment of excessive osteolysis with indolinone compounds
PCT/US2004/005283 WO2004075775A2 (en) 2003-02-24 2004-02-23 Treatment of excessive osteolyisis with indolinone compounds

Publications (1)

Publication Number Publication Date
MXPA05008961A true MXPA05008961A (es) 2005-11-04

Family

ID=32930497

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05008961A MXPA05008961A (es) 2003-02-24 2004-02-23 Tratamiento de osteolisis excesiva con compuestos de indolinona.

Country Status (11)

Country Link
US (1) US20040209937A1 (es)
EP (1) EP1599207A2 (es)
JP (1) JP2006518756A (es)
KR (1) KR20050113612A (es)
AU (1) AU2004216188A1 (es)
BR (1) BRPI0407793A (es)
CA (1) CA2516786A1 (es)
MX (1) MXPA05008961A (es)
NZ (1) NZ541825A (es)
PL (1) PL378762A1 (es)
WO (1) WO2004075775A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070119745A (ko) * 2005-05-12 2007-12-20 화이자 인코포레이티드 수니티닙 말레이트를 사용하는 항암 병행 요법
EP2112148A1 (en) * 2005-09-19 2009-10-28 Pfizer Products Inc. Solid salt forms of a pyrrole substituted 2-indolinone
AU2006342119B8 (en) * 2005-12-22 2013-05-09 Novartis Ag Soluble human M-CSF receptor and uses thereof
CN101367801B (zh) * 2007-08-15 2011-01-12 上海恒瑞医药有限公司 吡咯并六元n杂环羟基吗啡啉类衍生物的制备方法及其在医药上的应用
EP2318364A2 (en) * 2008-07-02 2011-05-11 Generics [UK] Limited Preparation of 3-pyrrole substituted 2-indolinone derivatives
US20110257237A1 (en) * 2008-07-10 2011-10-20 Generics [Uk] Limited Process for the preparation of crystalline forms of sunitinib malate
CN102239163A (zh) * 2008-07-24 2011-11-09 特瓦制药工业有限公司 通过乙酸舒尼替尼和它们的多晶型物制备苹果酸舒尼替尼的方法
WO2010011834A2 (en) * 2008-07-24 2010-01-28 Teva Pharmaceutical Industries Ltd. Sunitinib and salts thereof and their polymorphs
EP2181991A1 (en) * 2008-10-28 2010-05-05 LEK Pharmaceuticals D.D. Novel salts of sunitinib
EP2186809A1 (en) * 2008-11-13 2010-05-19 LEK Pharmaceuticals D.D. New crystal form of sunitinib malate
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
US10898211B2 (en) 2015-01-14 2021-01-26 Crossroads Extremity Systems, Llc Opening and closing wedge osteotomy guide and method
US10292713B2 (en) 2015-01-28 2019-05-21 First Ray, LLC Freeform tri-planar osteotomy guide and method
US10376268B2 (en) 2015-02-19 2019-08-13 First Ray, LLC Indexed tri-planar osteotomy guide and method
JP7140347B2 (ja) * 2016-06-09 2022-09-21 有機合成薬品工業株式会社 ４－（ピペリジン－４－イル）モルホリンの製造方法
JP2023514605A (ja) 2020-02-19 2023-04-06 クロスローズ エクストリミティ システムズ リミテッド ライアビリティ カンパニー ラピダスバニオン修復法のためのシステム及び方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73976C2 (uk) * 2000-02-15 2005-10-17 Суджен, Інк. Заміщені піролом 2-індолінони, фармацевтична композиція, спосіб модуляції каталітичної активності протеїнкінази та спосіб лікування або профілактики захворювання, пов'язаного з протеїнкіназою
AR042586A1 (es) * 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
JP2005508953A (ja) * 2001-10-10 2005-04-07 スージェン・インコーポレーテッド キナーゼ阻害剤としての３−［４−（置換ヘテロサイクリル）−ピロール−２−イルメチリデン］−２−インドリノン誘導体
US20040018528A1 (en) * 2002-05-17 2004-01-29 Sugen, Inc. Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals

Also Published As

Publication number Publication date
US20040209937A1 (en) 2004-10-21
AU2004216188A1 (en) 2004-09-10
EP1599207A2 (en) 2005-11-30
PL378762A1 (pl) 2006-05-15
WO2004075775A2 (en) 2004-09-10
KR20050113612A (ko) 2005-12-02
WO2004075775A3 (en) 2005-04-14
CA2516786A1 (en) 2004-09-10
JP2006518756A (ja) 2006-08-17
BRPI0407793A (pt) 2006-02-14
NZ541825A (en) 2008-11-28

Similar Documents

Publication Publication Date Title
MXPA05008961A (es) Tratamiento de osteolisis excesiva con compuestos de indolinona.
HUS2100051I1 (hu) Kompozíciók és eljárások sejtproliferációs rendellenességek kezelésére
MY184101A (en) Indoles
SG10201811480WA (en) Therapeutic compounds and compositions
MX2009006627A (es) Quinazolinas para la inhibicion de pdk1.
MY147364A (en) Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
GB2430935A (en) Tetrapeptide analogs
EP2298304A3 (en) Carboline derivatives useful in the treatment of cancer
SG132672A1 (en) 1,4-disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases
MX360404B (es) Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr.
TW200621230A (en) Anti-tumor compounds
TW200510301A (en) Novel compounds
GEP20084550B (en) Substituted morpholine compounds for the treatment of central nervous system disorders
TW200716141A (en) Compositions and methods for treatment for neoplasms
MX2009007075A (es) Metodos de uso para analogos de ciclopamina.
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
TN2011000298A1 (en) Compounds useful for inhibiting chk1
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
EA200970936A1 (ru) СОЕДИНЕНИЯ ПИРИДО[2,3-d]ПИРИМИДИН-7-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3K-АЛЬФА ДЛЯ ЛЕЧЕНИЯ РАКА
MX2009013069A (es) Tratamiento de leucemia resistente al imatinib.
WO2010027424A3 (en) 9-substituted phenanthrene based tylophorine derivatives
WO2019036417A3 (en) Inhibition of ngly1 for the treatment of cancer
UA96745C2 (en) PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
DE602005015329D1 (de) Rutheniumkomplexe zur krebsbehandlung
EA200971067A1 (ru) Триазолиламинопиримидиновые соединения